NRG Therapeutics
12 known investors
NRG Therapeutics is a clinical-stage neuroscience drug discovery company developing disease-modifying, oral small-molecule medicines that target mitochondrial function via inhibition of the mitochondrial permeability transition pore. Its pipeline addresses neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS/MND) and Parkinson's, with lead candidate NRG5051 entering a first-in-human trial.
Investors · 12
Also in the syndicate · 6
Funding
SEC filings, press & company announcements$67M disclosed across 1 round · 2025
- $67Mseries BSep 2025 · 4 sources
Dementia Discovery Fund (lead), SV Health Investors' Dementia Discovery Fund (lead), SV Health Investors' Dementia Discovery Fund (DDF) (lead), Brandon Capital, British Business Bank, Criteria Bio Ventures, M Ventures, Merck KGaA, Novartis, Novartis Venture Fund, Omega Funds, Parkinson's UK
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does NRG Therapeutics do?
- NRG Therapeutics is a clinical-stage neuroscience drug discovery company developing disease-modifying, oral small-molecule medicines that target mitochondrial function via inhibition of the mitochondrial permeability transition pore. Its pipeline addresses neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS/MND) and Parkinson's, with lead candidate NRG5051 entering a first-in-human trial.
- Who are NRG Therapeutics's investors?
- NRG Therapeutics's investors include Criteria Bio Ventures, Novartis Venture Fund, SV Health Investors, British Business Bank, Dementia Discovery Fund, M Ventures.
- How much funding has NRG Therapeutics raised?
- NRG Therapeutics has disclosed $67M raised across 1 round.